168 related articles for article (PubMed ID: 31273630)
1. Altered Expression of CD44, SIRT1, CXCR4, miR-21, miR-34a, and miR-451 Genes in MKN-45 Cell Line After Docetaxel Treatment.
Motamedi M; Razmkhah F; Rezakhani L; Ghasemi S
J Gastrointest Cancer; 2020 Jun; 51(2):520-526. PubMed ID: 31273630
[TBL] [Abstract][Full Text] [Related]
2. Frequency of CD44 positive cells in MKN45 cell line after treatment with docetaxel in two and three-dimensional cell cultures.
Alizadeh A; Rezakhani L; Anjom Shoa M; Ghasemi S
Tissue Cell; 2020 Apr; 63():101324. PubMed ID: 32223952
[TBL] [Abstract][Full Text] [Related]
3. Typhae pollen polysaccharides protect hypoxia-induced PC12 cell injury via regulation of miR-34a/SIRT1.
Wang S; Tang Q; Ge F; Guo Q
Int J Immunopathol Pharmacol; 2020; 34():2058738420910005. PubMed ID: 32635836
[TBL] [Abstract][Full Text] [Related]
4. Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells.
Lee SD; Yu D; Lee DY; Shin HS; Jo JH; Lee YC
Cancer Sci; 2019 Feb; 110(2):662-673. PubMed ID: 30485589
[TBL] [Abstract][Full Text] [Related]
5. Upregulated miR-132 in Lgr5
Zhang L; Guo X; Zhang D; Fan Y; Qin L; Dong S; Zhang L
Mol Carcinog; 2017 Sep; 56(9):2022-2034. PubMed ID: 28383763
[TBL] [Abstract][Full Text] [Related]
6. Hsa-miR-34a-5p reverses multidrug resistance in gastric cancer cells by targeting the 3'-UTR of SIRT1 and inhibiting its expression.
Deng XJ; Zheng HL; Ke XQ; Deng M; Ma ZZ; Zhu Y; Cui YY
Cell Signal; 2021 Aug; 84():110016. PubMed ID: 33894312
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of the miR-34a-SIRT1 axis inhibits breast cancer stemness.
Ma W; Xiao GG; Mao J; Lu Y; Song B; Wang L; Fan S; Fan P; Hou Z; Li J; Yu X; Wang B; Wang H; Wang H; Xu F; Li Y; Liu Q; Li L
Oncotarget; 2015 Apr; 6(12):10432-44. PubMed ID: 25826085
[TBL] [Abstract][Full Text] [Related]
8. DHA Abolishes the Detrimental Effect of Docetaxel on Downregulation of the MICA via Decreasing the Expression Level of MicroRNA-20a in Gastric Cancer.
Shekari N; Javadian M; Ghaffari S; Baradaran B; Darabi M; Kazemi T
J Gastrointest Cancer; 2020 Jun; 51(2):545-551. PubMed ID: 31368060
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer.
Zeng JF; Ma XQ; Wang LP; Wang W
World J Gastroenterol; 2017 Apr; 23(13):2337-2345. PubMed ID: 28428713
[TBL] [Abstract][Full Text] [Related]
10. Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer.
Shekari N; Asghari F; Haghnavaz N; Shanehbandi D; Khaze V; Baradaran B; Kazemi T
Anticancer Agents Med Chem; 2019; 19(3):304-309. PubMed ID: 30543177
[TBL] [Abstract][Full Text] [Related]
11. Replication Study: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44.
Yan X; Tang B; Chen B; Shan Y; Yang H;
Elife; 2019 Mar; 8():. PubMed ID: 30860027
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of miR-34a reduces cellular senescence in human adipose tissue-derived mesenchymal stem cells through the activation of SIRT1.
Mokhberian N; Bolandi Z; Eftekhary M; Hashemi SM; Jajarmi V; Sharifi K; Ghanbarian H
Life Sci; 2020 Sep; 257():118055. PubMed ID: 32634429
[TBL] [Abstract][Full Text] [Related]
13. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3.
Peng C; Huang K; Liu G; Li Y; Yu C
J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262
[TBL] [Abstract][Full Text] [Related]
14. Expression of microRNA-328 Functions as a Biomarker for Recurrence of Early Gastric Cancer (EGC) After Endoscopic Submucosal Dissection (ESD) by Modulating CD44.
Xue HG; Yang AH; Sun XG; Lu YY; Tian ZB
Med Sci Monit; 2016 Dec; 22():4779-4785. PubMed ID: 27923017
[TBL] [Abstract][Full Text] [Related]
15. MiR-199a-5p represses the stemness of cutaneous squamous cell carcinoma stem cells by targeting Sirt1 and CD44ICD cleavage signaling.
Lu RH; Xiao ZQ; Zhou JD; Yin CQ; Chen ZZ; Tang FJ; Wang SH
Cell Cycle; 2020 Jan; 19(1):1-14. PubMed ID: 31809227
[TBL] [Abstract][Full Text] [Related]
16. MiR-34a inhibits proliferation and migration of breast cancer through down-regulation of Bcl-2 and SIRT1.
Li L; Yuan L; Luo J; Gao J; Guo J; Xie X
Clin Exp Med; 2013 May; 13(2):109-17. PubMed ID: 22623155
[TBL] [Abstract][Full Text] [Related]
17. Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy.
Jang E; Kim E; Son HY; Lim EK; Lee H; Choi Y; Park K; Han S; Suh JS; Huh YM; Haam S
Biomaterials; 2016 Oct; 105():12-24. PubMed ID: 27497057
[TBL] [Abstract][Full Text] [Related]
18. Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles.
Liu Q; Li RT; Qian HQ; Wei J; Xie L; Shen J; Yang M; Qian XP; Yu LX; Jiang XQ; Liu BR
Biomaterials; 2013 Sep; 34(29):7191-203. PubMed ID: 23806972
[TBL] [Abstract][Full Text] [Related]
19. The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells.
Wang X; Yang B; Ma B
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1025-1031. PubMed ID: 27686228
[TBL] [Abstract][Full Text] [Related]
20. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells.
Akao Y; Noguchi S; Iio A; Kojima K; Takagi T; Naoe T
Cancer Lett; 2011 Jan; 300(2):197-204. PubMed ID: 21067862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
